The Danish Medicines Agency has unveiled a publicly available Investigator’s Brochure template designed specifically for cell therapy clinical trials, marking a significant step toward regulatory harmonization in advanced therapy medicinal products (ATMPs). The template aligns with European Medicines Agency guidelines and provides researchers with a structured framework for preparing compliant documentation without beginning from scratch.
Cell-based therapies present unique regulatory challenges compared to traditional pharmaceuticals, requiring comprehensive documentation on cell sourcing, manufacturing consistency, viability assays, and long-term follow-up protocols. By standardizing these critical elements, the DKMA’s template is expected to reduce administrative burden, improve submission quality, and accelerate regulatory review timelines across Nordic and European research institutions. This initiative facilitates more efficient development of innovative cell therapies while maintaining rigorous safety and quality standards.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: Danish Medicines Agency Launches Cell Therapy Clinical Trial Template →
